ReShape Lifesciences Inc. plans to list on the Nasdaq Capital Market under the symbol RSLS. It filed a Form S-1 registration statement for an initial public offering on December 20, 2024. As of November 6, 2026, its registration is amended and on file (Form S-1/A, February 14, 2025).
Sell to companies like ReShape Lifesciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
ReShape Lifesciences Inc. filed a Form S-1 registration statement for an initial public offering on 2024-12-20. It has amended it 6 times. As of its latest filing, on 2025-02-14, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
Also on the record for ReShape Lifesciences Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 28, 2026 | Leadership change: Jerry Leonard appointed, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
Check before you invest in ReShape Lifesciences Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on ReShape Lifesciences Inc. and the records around it.
ReShape Lifesciences Inc. elsewhere on the record
- Leadership changes Aug 2026
Watch ReShape Lifesciences Inc.
Get an email when ReShape Lifesciences Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ReShape Lifesciences Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on ReShape Lifesciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ReShape Lifesciences Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock is listed on the Nasdaq Capital Market under the symbol “RSLS.” On February 10, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $2.705 per share.From the S-1/A filed 2025-02-14
Shares offered
The terms of the Warrants will include a potential one-time reset of the exercise price (subject to a floor of $1.25 per share) and number of shares of our Common Stock underlying the Warrants and an alternative cashless exercise option that are applicable after effective date of the Warrant Stockholder Approval as described under “Description of the Securities We are Offering.” Under the alternative cashless exercise option under the Warrants, a Warrant holder could elect to receive 1.2 shares of common stock without the holder having to make any exercise payment.From the S-1/A filed 2025-02-14
Use of proceeds
We intend to use the net proceeds from this offering for general corporate purposes, including expenses related to our previously announced proposed merger with Vyome Therapeutics, Inc. and sale of substantially all of our assets to Ninjour Health International Limited, provided that under the terms of the Securities Purchase Agreement for the Convertible Note transaction with Ascent, we must use up to 50% of the net proceeds from any issuance of capital stock to prepay the amount we owe to Ascent under the Convertible Note.From the S-1/A filed 2025-02-14
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-12-20 | Registration statement filed | S-1 |
| 2025-01-15 | Registration statement amended | S-1/A |
| 2025-01-21 | Registration statement filed | S-1 |
| 2025-02-06 | Registration statement amended | S-1/A |
| 2025-02-07 | Registration statement amended | S-1/A |
| 2025-02-13 | Registration statement amended | S-1/A |
| 2025-02-14 | Registration statement amended | S-1/A |
| 2025-02-14 | Registration statement amended | S-1/A |
Tools for this story
Each opens in a new tab, filled in for ReShape Lifesciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.